Clinical Informatics News Product Brief 

 

December 4, 2014 | Thomson Reuters and Linguamatics today announced a collaboration combining Thomson Reuters’ Cortellis with Linguamatics I2E text analytics platform. The tool—Cortellis Informatics Clinical Text Analytics for I2E—uses a single user interface to apply Linguamatics’ I2E text mining platform to Cortellis content including clinical trial information, epidemiology data, literature, press releases and conference proceedings. 

 

Users will be able to glean new insights in support of trials, site selection and competitive intelligence, helping them to design more effective clinical trials and gain a deeper understanding of the implications of their results, the companies said. 

 

"We are excited about this innovative project with Thomson Reuters," said John Brimacombe, executive chairman of Linguamatics in a press release. "Combining the strength of our best of breed text analytics with the wealth of content within Cortellis will be a significant step forward for our clients in advancing productivity and efficacy in pharmaceutical R&D."  

 

Key features include:

• Authoritative, Hand-Curated Content: Users will be able to gain greater insights from their data with the combination of state-of-the-art text and high quality, hand curated content offered by Cortellis Informatics Clinical Text Analytics for I2E.  
• Access to Numeric Information: Advanced Text Analytics will allow for rapid extraction and connection of relevant facts and relationships within the content, improving speed to insight.  
• Data-Driven Clinical Insights: The ability to generate data tables from these resources will support users in preclinical studies, trial design, business intelligence, and provide a deeper understanding of the impact of clinical trials.  
• Streamlines Search Functionality: Fast, easy-to-use functionality allows for timely and accurate searches.  

 

"We are pleased to be working  with Linguamatics to provide the pharmaceutical industry with a solution that leverages the leading capabilities of both organizations and will provide our mutual customers with a stronger view into the clinical trial process," said Jon Brett-Harris, managing director of Thomson Reuters Life Science business in the press release announcement. "Our joint solution will make it easier for researchers to obtain the insights they need to help them make decisions that optimize the drug development process."

 

Press release.